WithdrawnPhase 1/2

The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications

Stopped: No funding

0Started 2021-11

Plain-language summary

The primary aim of this study is to determine whether Camostat mesylate reduces SARS-COV-2 associated coagulopathy. Additional aims are to determine the effect of Camostat mesylate on SARS-COV-2 associated myocardial injury, to assess duration of hypoxia or intubation, to evaluate the length of intensive care unit and hospital stay, and assess mortality rates.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. . Positive COVID-19 test result.
✓. Diagnosis of COVID-19 associated coagulopathy and cardiac complications based on D-Dimer, fibrinogen, TnT, CTPE, ischemic EKG changes
✓. Provision of informed consent. In patients with altered mental status consents can be obtained from the power of attorney.
✓. Stated willingness to comply with all study procedures and availability for the duration of the study
✓. Male or female, age 18 or older
✓. Diagnosed with hypoxia requiring intubation or positive air pressure.
✓. Diagnose with DVT/PE by ultrasound and CTPE and/or
✓. Elevated D-Dimer and/or

Exclusion criteria

✕. GFR\<30 mL/min
✕. Severe bleeding requiring blood transfusion of drop of 5% in HCT.
✕. Pregnancy or lactation
✕. Known allergic reactions to components of Camostat mesylate.
✕. Subjects under age 18

What they're measuring

Percent change in plasma D-Dimer

Timeframe: 7 days

Trial details

NCT IDNCT04435015

SponsorYale University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-12-31

View on ClinicalTrials.gov More Coagulopathy trials